Unraveling Chronic Cardiovascular and Kidney Disorder Through the Butterfly Effect

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Mar 13

PMID 38472936

Authors

Dimitri Bedo

Thomas Beaudrey

Nans Florens

Affiliations

Soon will be listed here.

Abstract

Chronic Cardiovascular and Kidney Disorder (CCKD) represents a growing challenge in healthcare, characterized by the complex interplay between heart and kidney diseases. This manuscript delves into the "butterfly effect" in CCKD, a phenomenon in which acute injuries in one organ lead to progressive dysfunction in the other. Through extensive review, we explore the pathophysiology underlying this effect, emphasizing the roles of acute kidney injury (AKI) and heart failure (HF) in exacerbating each other. We highlight emerging therapies, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, SGLT2 inhibitors, and GLP1 agonists, that show promise in mitigating the progression of CCKD. Additionally, we discuss novel therapeutic targets, including Galectin-3 inhibition and IL33/ST2 pathway modulation, and their potential in altering the course of CCKD. Our comprehensive analysis underscores the importance of recognizing and treating the intertwined nature of cardiac and renal dysfunctions, paving the way for more effective management strategies for this multifaceted syndrome.

Citing Articles

Lipoprotein(a) and the risk of type I cardiorenal syndrome in patients with coronary artery disease: A retrospective clinical study.

Jiang Z, Ma H, Meng J, Zhu D, Lu Y Int J Cardiol Heart Vasc. 2024; 56:101568.

PMID: 39720339 PMC: 11667174. DOI: 10.1016/j.ijcha.2024.101568.

Acute kidney injury as a key predictor of cardiovascular events in chronic kidney disease patients: the CKD-REIN study.

Florens N, Aymes E, Gauthier V, Frimat L, Laville M, Bedo D Clin Kidney J. 2024; 17(12):sfae337.

PMID: 39678250 PMC: 11646099. DOI: 10.1093/ckj/sfae337.

"Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions".

Moka M, K S, George M Acta Diabetol. 2024; 62(1):1-10.

PMID: 39254745 DOI: 10.1007/s00592-024-02363-5.

References

Liyanage T, Ninomiya T, Jha V, Neal B, Patrice H, Okpechi I . Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385(9981):1975-82. DOI: 10.1016/S0140-6736(14)61601-9. View

Tibi S, Zeynalvand G, Mohsin H . Role of the Renin Angiotensin Aldosterone System in the Pathogenesis of Sepsis-Induced Acute Kidney Injury: A Systematic Review. J Clin Med. 2023; 12(14). PMC: 10380384. DOI: 10.3390/jcm12144566. View

Mark P, Carrero J, Matsushita K, Sang Y, Ballew S, Grams M . Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study. Eur Heart J. 2023; 44(13):1157-1166. PMC: 10319959. DOI: 10.1093/eurheartj/ehac825. View

Schroder S, Gasterich N, Weiskirchen S, Weiskirchen R . Lipocalin 2 receptors: facts, fictions, and myths. Front Immunol. 2023; 14:1229885. PMC: 10451079. DOI: 10.3389/fimmu.2023.1229885. View

Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G . Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005; 46(2):320-7. DOI: 10.1053/j.ajkd.2005.04.031. View

Han Y, Xian Y, Gao X, Qiang P, Hao J, Yang F . Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway. Int Immunopharmacol. 2022; 113(Pt A):109396. DOI: 10.1016/j.intimp.2022.109396. View

Desai A, Webb D, Taubel J, Casey S, Cheng Y, Robbie G . Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023; 389(3):228-238. DOI: 10.1056/NEJMoa2208391. View

Karmakova T, Sergeeva N, Kanukoev K, Alekseev B, Kaprin A . Kidney Injury Molecule 1 (KIM-1): a Multifunctional Glycoprotein and Biological Marker (Review). Sovrem Tekhnologii Med. 2021; 13(3):64-78. PMC: 8482821. DOI: 10.17691/stm2021.13.3.08. View

Bayes-Genis A, De Antonio M, Vila J, Penafiel J, Galan A, Barallat J . Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2013; 63(2):158-66. DOI: 10.1016/j.jacc.2013.07.087. View

10.

Legrand M, Rossignol P . Cardiovascular Consequences of Acute Kidney Injury. N Engl J Med. 2020; 382(23):2238-2247. DOI: 10.1056/NEJMra1916393. View

11.

Palazzuoli A, Ruocco G, Beltrami M, Franci B, Pellegrini M, Lucani B . Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. Acute Card Care. 2014; 16(3):93-101. DOI: 10.3109/17482941.2014.911915. View

12.

Ishigami J, Cowan L, Demmer R, Grams M, Lutsey P, Carrero J . Incident Hospitalization with Major Cardiovascular Diseases and Subsequent Risk of ESKD: Implications for Cardiorenal Syndrome. J Am Soc Nephrol. 2020; 31(2):405-414. PMC: 7003293. DOI: 10.1681/ASN.2019060574. View

13.

Ng L, Squire I, Jones D, Cao T, Chan D, Sandhu J . Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure: A GREAT Network Study. J Am Coll Cardiol. 2017; 69(1):56-69. DOI: 10.1016/j.jacc.2016.10.038. View

14.

Wang J, He M, Li H, Chen Y, Nie X, Cai Y . Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis. J Am Heart Assoc. 2022; 11(7):e024417. PMC: 9075487. DOI: 10.1161/JAHA.121.024417. View

15.

Ronco C, Haapio M, House A, Anavekar N, Bellomo R . Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19):1527-39. DOI: 10.1016/j.jacc.2008.07.051. View

16.

Sumida M, Doi K, Ogasawara E, Yamashita T, Hamasaki Y, Kariya T . Regulation of Mitochondrial Dynamics by Dynamin-Related Protein-1 in Acute Cardiorenal Syndrome. J Am Soc Nephrol. 2015; 26(10):2378-87. PMC: 4587696. DOI: 10.1681/ASN.2014080750. View

17.

Ronco C, McCullough P, Anker S, Anand I, Aspromonte N, Bagshaw S . Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2009; 31(6):703-11. PMC: 2838681. DOI: 10.1093/eurheartj/ehp507. View

18.

Jungbauer C, Birner C, Jung B, Buchner S, Lubnow M, von Bary C . Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011; 13(10):1104-10. DOI: 10.1093/eurjhf/hfr102. View

19.

Pan Y, Li Q, Yan H, Huang J, Wang Z . Apela improves cardiac and renal function in mice with acute myocardial infarction. J Cell Mol Med. 2020; 24(18):10382-10390. PMC: 7521152. DOI: 10.1111/jcmm.15651. View

20.

Newsome B, Warnock D, McClellan W, Herzog C, Kiefe C, Eggers P . Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med. 2008; 168(6):609-16. DOI: 10.1001/archinte.168.6.609. View